Then, IGF2BP2 was highly expressed in thyroid cancer, and MALAT1 was found to up-regulate IGF2BP2 and enhance MYC expression via m6A modification recognition by competitively binding to miR-204 [38]. Here, IGF2BP2 is linked to thyroid gland carcinoma.